- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05256446
AMG 701 Expanded Access Program
February 15, 2022 updated by: Amgen
Expanded access requests for AMG 701 may be considered for adult patients with relapsed and/or refractory multiple myeloma whose disease is in partial response or better after AMG 420 therapy.
To request access, use Responsible Party contact information provided in this record.
Study Overview
Status
Available
Intervention / Treatment
Study Type
Expanded Access
Expanded Access Type
- Individual Patients
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
N/A
Description
Inclusion Criteria:
-
Exclusion Criteria:
-
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: MD, Amgen
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Registration Dates
First Submitted
February 15, 2022
First Submitted That Met QC Criteria
February 15, 2022
First Posted (Actual)
February 25, 2022
Study Record Updates
Last Update Posted (Actual)
February 25, 2022
Last Update Submitted That Met QC Criteria
February 15, 2022
Last Verified
February 1, 2022
More Information
Terms related to this study
Other Study ID Numbers
- AMG701 Expanded Access Program
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on AMG 701
-
AmgenWithdrawnRelapsed/Refractory Multiple Myeloma
-
CephalonCompletedPsoriasisUnited States
-
CephalonCompleted
-
BioMarin PharmaceuticalTerminatedLate-onset Pompe DiseaseUnited States, United Kingdom, Germany, France, Italy, Portugal, Belgium, Netherlands
-
Terns, Inc.Not yet recruitingChronic Myeloid Leukemia | Chronic Myeloid Leukemia, Chronic PhaseUnited States
-
BioMarin PharmaceuticalCompletedPompe DiseaseUnited States, United Kingdom, France, Australia, Germany
-
BioMarin PharmaceuticalTerminatedPompe DiseaseUnited States, United Kingdom, Australia, France, Germany, New Zealand
-
Millennium Pharmaceuticals, Inc.CompletedAdvanced Solid TumorsUnited States
-
TWi Biotechnology, Inc.CompletedEGFR Inhibitor-Induced Skin RashTaiwan
-
Ronald HoffmanNational Cancer Institute (NCI); Myeloproliferative Disorders-Research ConsortiumUnknownPolycythemia Vera | Essential Thrombocythemia | MyelofibrosisUnited States